The FDA recently approved a pretzel-shaped implant that helps some bladder cancer patients keep their bladder. Dr. Chris ...

Sequential therapy yields lower survival and response rates in upper tract urothelial carcinoma versus bladder cancer. Learn ...

Imagine a targeted approach to bladder cancer that spares healthy cells while delivering chemotherapy directly to cancerous ...

Squamous cell carcinoma (SCC) of the bladder is a distinct and rarer form, accounting for approximately 2% to 5% of all bladder cancers in the U.S. It develops in the flat, thin squamous cells that ...

When you learn you have bladder cancer, it’s only natural to ask: "Can I survive this, for how long, and can I expect to be cured?" You may have searched online for survival rate information. These ...

Keytruda and Padcev improve event-free and overall survival for adults with muscle invasive bladder cancer who cannot receive ...

Patients with initially low- or intermediate-risk primary tumors will often have a high-risk recurrence before progressing to more advanced disease, whereas primary high-risk tumors typically show ...

What Is Zusduri Used For? Zusduri is used to treat a certain type of recurrent, persistent bladder cancer known as LG-IR-NMIBC. About 75% of people with bladder cancer present with non-muscle invasive ...

Discover how the ALYREF biomarker predicts bladder cancer aggressiveness and boosts immunotherapy response. Find out more ...

The FDA has approved Pfizer and Astellas’ Padcev (enfortumab vedotin-ejfv) plus Merck’s Keytruda (pembrolizumab) as a perioperative treatment for adults with muscle-invasive bladder cancer who are ...

Astellas Pharma Inc. (ALPMY, 4503.T) announced that the European Medicines Agency (EMA) has validated for review a Type II variation application for PADCEV (enfortumab vedotin).

People with type 1 diabetes (previously called juvenile diabetes) are 4.29 times more likely to develop bladder cancer, ...